


EXHIBIT 1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner of Patents and Trademarks,
Washington, D.C. 20231, on March 17, 1995

PATENT

Attorney Docket No. 014643-000310

By 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
BERNS et al.) Examiner: B. Stanton
Serial No.: 08/216,121) Art Unit: 1804
Filed: March 22, 1994)
For: GENE TARGETING IN ANIMAL) DECLARATION UNDER 37 CFR §1.132
CELLS USING ISOGENIC DNA)
CONSTRUCTS)

)

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

I, Dr. Anton Berns, declare as follows:

1. I am a co-inventor of the above-referenced application. I am employed as the Head of the Division of Molecular Genetics at The Netherlands Cancer Institute in Amsterdam, The Netherlands, a position I have held since 1985. In addition, since January 1995 I have served as the Laboratory Research Coordinator at The Netherlands Cancer Institute. I have a concurrent appointment as a Professor in Experimental Molecular Genetics of Inherited Diseases at the University of Amsterdam which I have held since 1992. From 1992 until 1994, I also acted as Executive Vice President of Research and Development for Somatix Gene Therapy Corporation in Alameda, California.

2. My education includes a Masters degree in chemistry from the University of Nijmegen, The Netherlands, and a Ph.D. in biochemistry received from the University of Nijmegen in 1972. A copy of my *Curriculum Vitae* is attached as Exhibit A.

3. I am familiar with the prosecution of the above-referenced patent application and have reviewed the examiner's comments in the rejection of the claims under 35 USC §112, first paragraph. As I understand the examiner's position, he believes that the method disclosed in the above-referenced application would not be successful for loci other than the retinoblastoma susceptibility (Rb) locus. However, as explained in Paragraphs 4-5, *infra*, work done in my laboratory and by other researchers demonstrates that the use of isogenic DNA vectors as taught in the subject specification results in increased targeting efficiency at loci other than Rb. This result would have been expected by a scientist reading the subject disclosure because there was no evidence that the Rb locus would behave anomalously (*i.e.*, 'differently from most genes) as a site of homologous recombination.

4. Subsequent to the filing of the subject application, other scientists carrying out gene targeting at a variety of genetic loci have found significant increases in the ratio of homologous to non-homologous recombination events result when isogenic, rather than non-isogenic, DNA vectors are used.

i) For example, van Deursen and Wiering, *Nucleic Acids Research* 20:15, 3815-3820 (1992), used homologous recombination to introduce site-specific mutations into the creatine kinase M (CKM) gene of mouse ES cells. These researchers found that when an isogenic targeting vector was used, homologous recombination occurred at high frequency (*i.e.*, 12%). In contrast, when a nonisogenic vector was used no homologous recombination events were found (*i.e.*, a frequency of 0%). This paper clearly demonstrates that the use of isogenic DNA targeting constructs increases the ratio of homologous to non-homologous recombination events.

ii) As another example, Deng and Capecchi, *Molecular and Cellular Biology* 12:8, 3365-3371 (1992), carried out experiments using the HPRT locus in mouse ES cells. These authors reported that vectors prepared from isogenic DNA targeted four to five times more frequently than corresponding vectors from nonisogenic DNA, demonstrating an increase in correct gene targeting at the HPRT locus by use of isogenic DNA vectors.

iii) As another example, Deng *et al.*, *Molecular and Cellular Biology* 13:4, 2134-2140 (1993), used a replacement vector containing isogenic DNA to introduce a mutation into the mouse cystic fibrosis transmembrane regulator (CFTR) gene in order to create a mouse model for human cystic fibrosis. Deng *et al.* noted that the targeting frequency

achieved by them was significantly higher than that reported by other investigators (i.e., Koller *et al.*, reference 10 of Deng *et al.*) who used a similar replacement type vector containing non-isogenic DNA (see Deng *et al.* at page 2139, column 1, lines 15-20). In hypothesizing that this difference in targeting frequency may be due to the use of an isogenic DNA vector, Deng *et al.* cited the publication by myself and my coinventors disclosing the subject invention (te Riele *et al.*, 1992, *Proc. Natl. Acad. Sci. (USA)* 89:5128-5132). Copies of the van Deursen and Wiering, Deng and Capecchi, Deng *et al.* and Koller *et al.* references are enclosed with the accompanying Form PTO-1449.

iv) The results reported in the three references described *supra* demonstrate that the use of isogenic DNA vectors targeted to a variety of genes results in significant increases in the ratio of homologous to non-homologous recombination, as taught by the subject application. The method taught in the subject application is clearly not limited to any particular gene or locus.

5. In addition, work done by me or under my supervision has demonstrated that following the teachings of the subject application, use of isogenic targeting vectors results in high ratios of homologous to non-homologous recombinants at several loci in addition to the Rb locus. The results of several experiments carried out using mouse ES cells are summarized in Table 1, *infra*. These experiments do not represent direct side-by-side comparisons using targeting vectors with isogenic and nonisogenic DNA. However, based on my knowledge of the literature in this field, the high targeting efficiency observed indicates that using isogenic DNA vectors results in an increased ratio of homologous to non-homologous recombination at each of the loci tested. The experiments that generated the results for three of the loci listed in Table 1 have been described in scientific publications, copies of which are enclosed with the accompanying Form PTO-1449.

Table I

Locus	% Correct Gene Targeting
mdria ¹	10%
bmi-1 ²	14%
IL2R τ	30%
bcl-3	7%
NF-2	40%
E12 ³	40%
Frat-1	12%
P107 (Rb related gene)	30%
rep3	3%
CD44	10%
integrin- β 4	9%

¹ Schinkel et al., *Cell* 77:491-502, (1994)

² van der Lught et al., *Genes & Development*: 8:757-769 (1994)

³ Bain et al., *Cell* 79:885-892 (1994)

6. The results in Table 1, *supra*, together with the results reported by other researchers using isogenic targeting vectors as described in Paragraph 4, also demonstrate that the method of the subject invention is useful for producing populations of cells where between about 10% and 90% of the cells exhibit correct gene targeting.

7. As I understand the examiner's position, he believes that the method disclosed in the above-referenced application would not work for cells other than mouse ES cells. I am not aware of, nor do I find in the examiner's comments in the Office Action, any

scientific reason to support this assertion. I know of no data suggesting that the fundamental systems dealing with extrachromosomal recombination in ES cells is unique or different from that generally found in other somatic cells. On the contrary, a scientist would expect ES cells and other somatic cells to have similar properties. For example, Charron *et al.* *Molecular and Cellular Biology* 10:4, 1799-1804 (1990) described experiments using the vector pJC7, encoding n-myc and using a neomycin resistance/promoter selection system, for gene targeting in ES cells and in pre-B cell lines. Charron *et al.* reported that the targeting frequency in two pre-B cell lines was comparable to the frequency in ES cells (see Table 2 of Charron *et al.* showing targeting frequencies of 17% and 22% in pre-B cells, and frequencies of 0%, 0%, 44.4%, 100%, 25%, 16.7% and 26.7% in ES cells). The results reported by Charron *et al.* are consistent with the view held by scientists that there is no reason to believe that the fundamental aspects of extrachromosomal recombination differ between mouse ES cells and other mammalian cells. The Charron *et al.* reference is enclosed with the accompanying Form PTO-1449.

8. I have reviewed the examiner's comments in the rejection of claims under 35 USC §103. As I understand the examiner's position, he understands the comments of Capecchi, *Science* 244:1288-1292 (1989), and Sedivy and Sharp, *Proc. Natl. Acad. Sci. (USA)* 86:227-231 (1989), regarding the "extent of homology" to refer to the level of sequence identity between input and chromosomal sequences. However, a scientist reading these references would understand that these authors are referring to the *length* of the regions of homologous DNA and *not* to the degree of homology (*i.e.*, degree of sequence identity). For example, the Capecchi reference at page 1289, column 2, lines 11-17 clearly indicates that the "extent of sequence homology" can be described as ranging (in the experiments discussed) "from 2.9 to 14.3 kb." This is clearly a description of length and not sequence identity.

9. Similarly, in the Sedivy reference "extent of homology" is plainly used to refer to *length*, as shown at page 230, column 2, last paragraph, lines 8-11. See also page 231, bridging sentence, referring to "larger" (*i.e.*, longer) homologous sequences. The sentence in the Sedivy reference particularly cited by the examiner for teaching "maximization of

homology" (Sedivy *et al.*, page 227 first column, first paragraph, lines 15-21) does not refer to work by Sedivy but to Sedivy's references 3 and 5. Sedivy's reference 3 (Lin *et al.*, 1985, *Proc. Natl. Acad. Sci. (USA)* 82:1391-5) and reference 5 (Thomas and Capecchi, 1987, *Cell* 51:503-12) are enclosed with the accompanying Form PTO-1449. Neither of these references discusses or teaches maximization of sequence identity or the advantages of using isogenic DNA constructs. The paper by Thomas and Capecchi includes only experiments in which the *length* of the homologous region between target and vector is varied (see, e.g., Table 3 of that paper). Similarly, Lin *et al.* describe the deletion of regions of the targeting vector, and not differences in sequence identity.

10. As I understand the examiner's position, the examiner also maintains that one of skill reading Waldman *et al.* (1988) would appreciate the importance of the degree of sequence identity in gene targeting as disclosed in the subject application. However, Waldman *et al.* do not teach gene targeting but instead, describe *intramolecular* recombination. A scientist would not have extrapolated Waldman's results with intramolecular targeting to the design of a gene targeting vector for a number of reasons, some of which are listed below.

i) Intramolecular targeting differs from gene targeting (*i.e.* integration of gene targeting vectors by extrachromosomal recombination) in a number of ways. For example, it was known that these processes are effected by different mechanisms (see Klein, 1984, *Nature* 310: 748-753) and have fundamentally different cellular consequences.

Intrachromosomal recombination between related chromosomal sequences is generally harmful to a cell and must be suppressed. By contrast, extrachromosomal recombination may have an essential role in cellular physiology in effecting repair of double-stranded DNA breaks and may therefore need to be facilitated. These different physiological roles would have suggested that stricter sequences requirements would apply for intrachromosomal than extrachromosomal recombination so that latter occurs with greater efficiency than the former.

ii) An earlier paper by Waldman and Liskay, *Proc. Natl. Acad. Sci. (USA)* 84: 5340-5344 (1987), indicated that the degree of sequence identity required for intramolecular recombination was greater than required for intermolecular recombination. These authors studied the effects of a 19% base-pair mismatch on genetic recombination and found that intrachromosomal recombination was reduced by a factor of greater than 1000, while

extrachromosomal recombination was reduced only 3- to 15-fold. The authors noted that "Our results suggest differences between the mechanisms of extrachromosomal and intrachromosomal recombination in mammalian cells." In view of this manifest difference in sequence specificity of intra- and extrachromosomal recombination a scientist would not have expected the Waldman (1988) publication regarding intrachromosomal recombination to have applied to gene targeting (*i.e.*, extrachromosomal) systems.

iii) The experiments described by Waldman on intracellular recombination were performed on segments of DNA much smaller (*i.e.*, 360 bp) than those typically used in gene targeting (several kb). Waldman states that "efficient [intramolecular] recombination appears to require between 134 and 232 bp of uninterrupted homology" (abstract). In view of the teaching of Capecchi and others of the importance of the length of targeting DNA in obtaining high efficiency in gene targeting, the purported identification of a targeting unit in the context of a DNA segment having a length of less than 232 bp would have been of little predictive value in the context of the much larger targeting DNA segments used in gene targeting.

iv) For these and other reasons a scientist studying *gene targeting* would not have understood the work by Waldman *et al.* on *intramolecular* recombination to suggest that isogenic DNA vectors would result in considerable increases in the frequency of homologous recombination.

11. The examiner contends that prior to the disclosure of the subject invention, a scientist would have been motivated to use an isogenic targeting vector to optimize targeting efficiency "in any situation in which targeting efficiency was low." However, prior to the disclosure of the instant invention numerous scientific publications described efforts to increase targeting efficiency. A variety of approaches were suggested by others, including increasing the length of the homologous DNA, development of the PNS (positive-negative selection) system, and use of constructs lacking an essential element (*i.e.*, promoters, translation initiation or polyadenylation sites) that were recovered upon recombination. However, no publication of which I am aware suggested that using isogenic DNA would result in a dramatically increased frequency of homologous recombination as disclosed in the subject application.

12. Furthermore, in the absence of a compelling motivation such as that provided by the subject invention, a scientist would not have taken the special steps required to use isogenic DNA vectors for gene targeting. A scientist, intending to target a particular gene, would typically use a homologous clone that was easily available. Prior to the disclosure by myself and my co-inventors, the advantage of an extremely high (e.g., greater than about 99.5%) level of sequence identity was not understood. In the absence of this understanding scientists did not go to the considerable time, effort and expense of using isogenic DNA constructs. Following the discovery of the advantages of using isogenic DNA vectors by myself and my co-inventors, the practice of scientists in the field changed. For example, a large proportion of the research carried using gene targeting is carried out using mouse ES cells. Most mouse ES cells are derived from the 129 strain of mouse. In contrast, at the time of invention, most of the mouse genomic libraries used for gene targeting in these ES cells were derived from the BALB/c or Black 6 mouse strains. Prior to our discovery of the advantages of isogenic DNA vectors, experts in the field believed that because the genomic DNA contained in the 129 ES cells and the vector DNA found in BALB/c and Black 6 (BL6) genomic DNA libraries were homologous (*i.e.*, they were both from mouse) that these cells and vectors were well matched for gene targeting studies.

13. However, following our discovery, workers in the field became aware of the advantages of using isogenic DNA and have, in many cases, modified their protocols to use isogenic DNA vectors. Since disclosure of the advantages of using isogenic targeting vectors, researcher in numerous laboratories around the world have contacted my laboratory with requests for aliquots of a genomic library made from mouse strain 129 cell DNA to use in conjunction with their strain 129 ES cells. I have attached as Exhibits B-P letters from investigators requesting aliquots of the strain 129 genomic library. These requests demonstrate acknowledgement by members of the scientific community of the advantages of using isogenic DNA vectors. They also demonstrate that researchers targeting 129 ES cells had not, prior to the disclosure of our invention, been motivated to use isogenic DNA for constructing gene targeting vectors. I estimate that I have received more than twenty-five such requests.

14. As I understand the examiner's comments at page 11 of the Office Action, he suggests that it would have been obvious to one of skill to use isogenic DNA constructs to increase the efficiency of gene targeting. However, in my opinion as an expert in the field, the position set forth by the examiner include reasoning that is contrary to accepted scientific belief or, at best, unsupported by experimental evidence.

15. For example, the examiner's argument appears to rest on the theory that homologous recombination is dependent on nucleation between the vector DNA and the genomic target DNA. Nucleation is described as "an essentially unimolecular collision reaction" that is a critical, rate-limiting step in the homologous recombination reaction. In my opinion the examiner misconceives the process of homologous recombination and the conditions under which recombination occurs. Homologous recombination involves cellular machinery such as recombinases, endonucleases, repair enzymes, DNA binding proteins, and possibly such incompletely characterized processes as strand invasion and long patch mismatch repair. Homologous recombination is simply not comparable to collision reactions occurring between simple molecules in solution. Notably, if recombination occurs as a unimolecular collision, as described by the examiner, one would expect that the rate of recombination would depend on the concentration of vector DNA introduced into the cell. However, there is no evidence to support this notion.

16. The examiner also suggests that the results disclosed the subject application could be accounted for by fortuitous presence of "particular 5 base pair region[s]" that are "critical" to the nucleation reaction (Office Action at page 11, lines 19-21). However, experiments carried out by me or under my supervision indicate that particular "recombinogenic" sequences do not account for the surprising results obtained using isogenic DNA vectors. We constructed two vectors comprising corresponding regions from the mouse Rb locus. One vector was made using DNA from strain 129 mice; the second was made using DNA from Balb/c mice. Gene targeting experiments using ES cells derived from 129 or BALB/c strain mice were carried out essentially as described in the specification. The results are summarized in Table II. If there were, e.g., a recombinogenic stretch in, for example, the 129 strain DNA it would be expected that using this DNA would result in a higher frequency of homologous recombination without regard to the strain of ES cells used.

However, targeting efficiency was considerably greater (by more than an order of magnitude) when either DNA vector was used with ES cells from the corresponding strain, compared to either DNA vector used with ES cells of a different strain. These results demonstrate that it is the *isogenicity* of the target DNA and the targeting vector that results in higher targeting efficiency, not any *particular* sequence present.


Table II

Mouse strain from which vector DNA is derived	Source of ES cells	% Correct Gene Targeting (homologous recombination/non-homologous recombination)
129 strain	129 strain	26% (33/94)
129 strain	BALB/c strain	0.6% (1/144)
BALB/c strain	129 strain	1.4% (1/68)
BALB/c strain	BALB/c strain	18% (16/72)

I have been duly warned that willful false statements and the like are punishable by fine and imprisonment or both under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the above-identified patent application or any patent issuing thereon.

Respectfully submitted,

Dated: March 14, 1995


Anton Berns, Ph.D.

CURRICULUM VITAE

<u>Name</u>	Berns, Anton J.M.
<u>Born</u>	January 3, 1945
	Schijndel, The Netherlands
<u>Education</u>	
1957 - 1963	Gymnasium-B, Canisius College, Nijmegen
1963 - 1969	Masters degree Chemistry (with honors) in Biochemistry, Organic Chemistry and Physical Chemistry University of Nijmegen, The Netherlands
1969 - 1972	Ph.D. study (Supervisor Prof.Dr. H. Bloemendaal) Thesis (with honors): Isolation of calf lens mRNA and its translation in heterologous systems University of Nijmegen.
1972	2-months visit Massachusetts Institute of Technology (Dept. Drs. A. Rich and D. Baltimore)
1972 - 1974	Junior staff member Department of Biochemistry, University of Nijmegen, The Netherlands
1974 - 1976	Postdoc Salk Institute, San Diego, California
1975	Animal Virology Course, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
1976 - 1985	Senior staff member Dept. of Biochemistry, University of Nijmegen, The Netherlands
1979	6 months visiting scientist Salk Institute
1985 - present	Head Div. Molecular Genetics, The Netherlands Cancer Institute, Amsterdam, The Netherlands
1992 - present	Professor in Experimental Molecular Genetics of Inherited Diseases, University of Amsterdam
1992 - 1994	Executive Vice President R&D of SomaGen Gene Therapy Corporation, Alameda, Cal.
1995 -	Laboratory Research Coordinator, Netherlands Cancer Institute.
<u>Honors</u>	
1972	Travel stipend from SHELL
1973	Gold medal award of the Chemical Society, The Netherlands
1993	Biology Prize "Antoine de Lacassagne" of The French Cancer Society
<u>Memberships etc.:</u>	
1989 - present	Member "Scientific Board of the Dutch Cancer Society"
1990 - present	Member EMBO
1989 - 1991	Chairman Genetic Society
1989 - present	Member committee "Genetics and Virology", NWO
1992 - present	Chairman committee "Genetics and Virology", NWO
	Groupleader Working groups NWO: SON (nucleic acids), SLW (Molecular developmental biology of animals, GMW (persistent virus infections and oncogenic transformation)
1991-1994	Co-organizer Mouse Molecular Genetics Meetings (Cold Spring Harbor/Heidelberg)
<u>Editorial Boards:</u>	
1991 -	BBA, Reviews in Cancer
1995-98	EMBO J.
1995 -	Genes & Development

Accepted invited lectures from July 1992

- Parijs, Institut Pasteur. Seminar 2-3 juli 1992. Multistep tumorigenesis: Effects of gain- and loss-of-function mutations in oncogenes and tumor suppressor genes in transgenic mice.
- London, Wellcome Summer School on Gene targeting and homologous recombination. 9-18 juli 1992. Targeted disruption of the pim-1 oncogene and the retinoblastoma tumor suppressor gene.
- Marburg, 3rd IMT Symposium. 5-7 oktober 1992: Multistep transformation: tumor induction in mice with gain-of-function and loss-of-function mutations in oncogenes and tumor suppressor genes.
- Cape Cod, AACR "Normal and Neoplastic Growth and Development", 18-22 oktober 1992. Tumor induction in mice with gain- and loss-of-function mutations in oncogenes and tumor suppressor genes.
- Tübingen, Somatic Gene Therapy- Gene transfer and Differentiation. 4-8 November 1992. Gain- and loss-of-function mutations in mice to identify new oncogenes and to determine their mechanism of action.
- Köln, Ernst Klenk Conference on "Regulation of Cell Growth". 8-10 november 1992. Oncogenes and growth factors.
- Lausanne 2nd ISREC Conference, 14-15 januari 1993. Genetic damage and escape from proliferation control. Multistep transformation in mouse model systems.
- Big Sky, AACR 1-5 februari, 1993. "Oncogenes and antioncogenes in differentiation, development and human cancer. Identification and characterization of synergizing oncogenes."
- Salk Institute, La Jolla. Seminar. Mouse model systems to study oncogenes and tumor suppressor genes.
- Brussel, EACR 7 april. Identification of collaborating oncogenes in lymphomagenesis: effects of gain- and loss of function.
- IMP Seminar, 8 april 1993. Identification of collaborating oncogenes in lymphomagenesis: effects of gain- and loss of function.
- University of Pittsburg. Seminar. Mouse model systems to identify and characterize synergizing oncogenes and tumor suppressor genes.
- Los Angeles, AMGEN. Seminar. Mouse model systems to identify and characterize synergizing oncogenes and tumor suppressor genes. Round table discussion about Somatix Gene Therapy programs
- Copper Mountain, FASEB Meeting on Cellular and Molecular Genetics. Juli 11-16, 1993. Identification and characterization of synergizing oncogenes.
- Stanford, Beckman Institute, Seminar. Identification and characterization of synergizing oncogenes.
- San Francisco, CHI conferences. 22-23 september, 1993. Identification and characterization of synergizing oncogenes.

- Heidelberg. Gene Diagnosis and Gene Therapy. 4-6 oktober, 1993. Tumor induction in mice with gain- and loss-of-function mutations in oncogenes and tumor suppressor genes.
- Seattle, Hutchinson Cancer Center. 21 oktober, 1993. Mouse model systems to identify and characterize synergizing oncogenes.
- Strassbourg, Human Frontier Science Program Symposium. 19 november 1993. Final report on collaboration with S. Tonegawa and M. Hooper on T cell receptor mutant mice (transgenics/K.O.).
- Ein Gedi, Israel. february 28 - March 4, 1994. Gene Therapy Conference. Immunotherapy using tumor vaccines transduced with GM-CSF
- UCSF. Seminar. Identification and characterization of synergizing oncogenes
- Noordwijk, April 23-26, 1994. The Netherlands. 4th European workshop on cytogenetics and molecular genetics of human solid tumors. Lecture: Mouse models to identify genes involved in initiation and progression of tumorigenesis.
- Vienna. May 23-25, 1994. IMP Conference " Molecular mechanisms of human disease". Mouse model systems to study multistep tumorigenesis
- Cold Spring Harbor. June 1-8. Symposium. Molecular Genetics of Cancer. Mouse model systems to study multistep tumorigenesis.
- Bar Harbor. August 29, 1994. Jackson Laboratory. Mouse model systems to identify and characterize collaborating oncogenes.
- Cold Spring Harbor. September 1-5, 1994. Mouse Molecular Genetics Meeting. Co-organizer (together with Andy McMahon, Robb Krumlauf and Liz Robertson).
- Amsterdam, September 6-10, 1994. EORTC Breast Cancer working conference. Gene therapy approaches to treat cancer. A Sisiphan task?
- New Delhi, September 19-22, 1994 16th International Congress of Biochemistry and Molecular Biology. Mouse model systems to study the multistep process of tumorigenesis.
- Fulgsozentret, Denmark. October 20., 1994. Key note address. Danish Biochemistry Society. Mouse model systems to study the multistep process of tumorigenesis.
- Ein Gedi Israel. November 28 - December 2, 1994. 9th Maimonides Conference. Genes collaborating with myc in tumorigenesis.
- Keystone, Oncogenes, 20 years later. Jan 5-11, 1995. Identification and characterization of collaborating oncogenes in genetically manipulated mice.
- Zürich, March 15-17 1995. Meeting of Charles Rodolphe Bruppacher Foundation. Genetic predisposition to Cancer.
- Madrid, April 24-28. Nuclear oncogenes and transcription factors in hematopoietic cells. Identification and characterization of synergizing oncogenes in lymphomagenesis.

- Mosbach, Germany. April 27-29. Mosbacher Colloquium. The biochemistry and molecular biology of tumor development. Basic science at the doorstep of clinical medicine.
- Vienna, May 11-13, 1995. IMP Conference. Interfaces between Cancer and Development.
- San Francisco, July 23-29, 1995. Leukemogenesis and proto-oncogenes. Immunology Congress.
- Heidelberg, August 23-27, 1995. Mouse Molecular Genetics Meeting.

Grant support last 5 years

Program Grant NWO 1988-1993. Targeted disruption of genes. fl 1.500,000

Program grant NWO 1994-1999. Generation of mutant mouse model systems fl 1.400.000

Human Frontier Science Program Grant (With S. Tonegawa and M. Hooper) \$ 750,000

STW/pharmaceutical Industries 1986-1992. fl 1.500,000

Dutch Cancer Society (NKB) : NKI 88-03, 1988-1992, fl 600,000
: NKI 89-17, 1989-1993, fl 600,000
: NKI 90-11, 1990-1994, fl 800,000
: NKI 90-12, 1990-1994, fl 600,000
: NKI 92-48, 1992-1996, fl 500,000
: NKI 94-771, 1994-1998, fl 900,000

Publications

Berns, A.J.M., A. Zweers, A.A.M. Gribnau and H. Bloemendaal. Proteolytic activity of partly purified ribonuclease inhibitor from rat liver. *Biochim. Biophys. Acta* 247: 62-65, 1971.

Berns, A.J.M., R.A. de Abreu, M. van Kraalkamp, E.L. Benedetti and H. Bloemendaal. Synthesis of lens protein in vitro. V. Isolation of messenger-like RNA from lens by high resolution zonal centrifugation. *FEBS Letters*, 18: 159-163, 1971.

Gielkens, A.L.J., A.J.M. **Berns** and H. Bloemendaal. An efficient procedure for the isolation of polyribosomes from tissue culture. *Eur. J. Biochem* 22: 478-484 1971.

Bloemendaal, H., A.J.M. **Berns**, G. Strous, M. Mathews, and C.D. Lane. Translation of eukaryotic messenger RNA in various heterologous systems. In: *RNA Viruses/Ribosomes*. North Holland, Amsterdam, 1972, pp. 237-250.

Bloemendaal, H., A.J.M. **Berns**, A. Zweers, H. Hoenders and E.L. Benedetti. The state of aggregation of α -crystallin detected after large-scale preparation by zonal centrifugation. *Eur. J. Biochem* 24: 401-406, 1972.

Mathews, M.B., M. Osborn, A.J.M. **Berns** and H. Bloemendaal. Translation of two messenger RNAs from lens in a cell free system from Krebs II ascites cells. *Nature New Biology* 236: 5-7, 1972.

Berns, A.J.M., G.J.A.M. Strous and H. Bloemendaal. Heterologous in vitro synthesis of lens α -crystallin polypeptide. *Nature New Biology*, 236: 7-9, 1972.

Berns, A.J.M., M. van Kraalkamp, H. Bloemendaal and C.D. Lane. Calf crystallin synthesis in frog cells: The translation of lens-cell 14S RNA in Oocytes. *Proc. Nat. Acad. Sci. USA* 69: 1606-1609, 1972.

Strous, G.J.A.M., A.J.M. **Berns**, H. van Westreenen and H. Bloemendaal. Synthesis of lens protein in vitro. Role of methionyl-tRNAs in the synthesis of calf-lens α -crystallin. *Eur. J. Biochem.* 30: 48-52, 1972.

Bloemendaal, H., A.J.M. **Berns**, F. van der Oudera and W.W.W. de Jong. Evidence for a 'non-genetic' origin of the A1 chains of α -crystallin. *Exp. Eye Res.* 14: 80-81, 1972.

Berns, A.J.M., V.V.A.M. Schreurs, M.W.G. van Kraalkamp and H. Bloemendaal. Synthesis of lens protein in vitro. Translation of calf-lens messengers in heterologous systems. *Eur. J. Biochem.* 33: 551-557, 1973.

Berns, A.J.M., H. Bloemendaal, S.J. Kaufman and I.M. Verma. Synthesis of DNA complementary to 14S calf lens crystallin messenger RNA by reverse transcriptase. *Biochem. Biophys. Res. Comm.* 52: 1013-1019, 1973.

Favre, A., U. Bertazzoni, A.J.M. **Berns** and H. Bloemendaal. A poly A content and secondary structure of the 14S calf lens messenger RNA. *Biochem. Biophys. Res. Comm.* 56: 273-280, 1974.

Piperno, G., U. Bertazzoni, A.J.M. **Berns** and H. Bloemendaal. Calf lens crystallin messenger RNA's contain polynucleotide sequences rich in adenylic acid. *Nucl. Acids Res.* 1: 245-258, 1974.

Strous, G.J.A.M., A.J.M. **Berns** and H. Bloemendaal. N-terminal acetylation of the nascent chains of α -crystallin. *Biochem. Biophys. Res. Comm.* 58: 876-884, 1974.

Berns, A., P. Jansen and H. Bloemendaal. The separation of α - and β -rabbit globin mRNA by polyacrylamide gel electrophoresis. *FEBS Letters* 47: 343-347, 1974.

Berns, A. and H. Bloemendal. Translation of mRNA from vertebrate eye lens. *Enzymology* 30: 675, 1974.

Berns, A., M. Salden, D. Bogdanovsky, M. Raymondjean, G. Schapira and H. Bloemendal. Non-specific stimulation of cell-free protein synthesis by a dialyzable factor isolated from reticulocyte initiation factors ("tRNA"). *Proc. Natl. Acad. Sci. USA* 72: 714-718, 1975.

Salden, M., T. Bisseling, A. **Berns** and H. Bloemendal. Requirement of a dialyzable component from crude initiation factors for the translation of viral and eukaryotic messenger RNA. *Biochem. Biophys. Res. Commun.* 65: 317-322, 1975.

Jaenisch, R., A. **Berns**, J. Dausman and V. Cox. Germ line integration and leukemogenesis of exogenous and endogenous murine leukemia viruses. *ICN-UCLA conference on Animal Virology*. D. Baltimore, A.S. Huang and T. Fos (eds.). Acad. Press, New York, 1976, pp. 283-310.

Berns, A.J.M. and H. Bloemendal. Cytoplasmic Messenger RNA. In: *Handbook of Genetics* Vol.5, R.C. King (ed.). Plenum Press, New York, 1976, pp. 267-303.

Berns, A.J.M. and R. Jaenisch. Increase of AKR-specific sequences in tumor tissues of leukemic AKR mice. *Proc. Natl. Acad. Sci. USA* 73: 2448-2452, 1976.

Jaenisch, R. and A.J.M. **Berns**. Tumor virus expression during mammalian embryogenesis. In: *Concepts in Mammalian Embryogenesis*. M.I. Sherman (ed.). MIT Press, Cambridge, Mass. 1977, pp. 267-314.

Van der Putten, H., E. Terwindt, A.J.M. **Berns** and R. Jaenisch. The integration sites of endogenous and exogenous Moloney murine leukemia virus. *Cell* 18: 109-116, 1979.

Colombatti, A., A. Dux, A. **Berns**, P. Demant and J. Hilgers. H-2 dependent regulation of high ecotropic MuLV expression. *J. Natl. Cancer Inst.* 63, 869-873, 1979.

Jones, M., R.A. Bosseiman, F.A. van der Hoorn, A.J.M. **Berns**, H. Fan and I.M. Verma. Identification and molecular cloning of Moloney mouse sarcoma virus-specific sequences from uninfected mouse cells. *Proc. Natl. Acad. Sci. USA* 77: 2651-2655, 1980.

Berns, A.J.M., M.H.T. Lal, R.A. Bosseiman, M.A. McKennett, L.T. Bacheler, H. Fan, E.C. Robanus Maandag, H. van der Putten and I.M. Verma. Molecular cloning of unintegrated and a portion of integrated Moloney murine leukemia viral DNA in bacteriophage lambda. *J. Virol.* 36: 254-263, 1980.

Verma, I.M., M.-H.T. Lal, R.A. Bosseiman, M.A. McKennett, H. Fan and A. **Berns**. Molecular cloning of unintegrated Moloney mouse sarcoma viral DNA in bacteriophage λ . *Proc. Natl. Acad. Sci. USA* 77: 1773-1777, 1980.

Van Beveren, Ch., J.G. Goddard, A. **Berns** and I.M. Verma. Structure of Moloney murine leukemia viral DNA: Nucleotide sequence of the 5' long terminal repeat and adjacent cellular sequences. *Proc. Natl. Acad. Sci. USA* 77: 3307-3311, 1980.

Van Beveren, Ch., J.A. Galleshaw, V. Jonas, A.J.M. **Berns**, R.F. Doolittle, D.J. Donoghue and I.M. Verma. Nucleotide sequence and formation of the transforming gene of a mouse sarcoma virus. *Nature* 289: 258-262, 1981.

Van der Putten, H., W. Quint, J. van Raaij, E. Robanus Maandag, I.M. Verma and A. **Berns**. M-MuLV-induced leukemogenesis: Integration and structure of recombinant proviruses in tumors. *Cell* 24: 729-739, 1981.

Quint, W., W. Quax, H. van der Putten and A. Barns. Characterization of AKR-murine leukemia virus sequences in AKR mouse substrains and structure of integrated recombinant genomes in tumor tissues. *J. Virol.* 39: 1-10, 1981.

Gielkens, A.L.J. and A. Barns. Differentiation of Aujeszky's disease virus strains by restriction endonuclease analysis of the viral DNAs. In: *Aujeszky's disease*. G. Wittmann and S.A. Hall (eds.), *Current topics in veterinary medicine and animal science*. Vol. 17. Martinus Nijhoff, The Hague, 1982, pp. 3-13.

Van der Putten, H., W. Quint, I.M. Verma and A. Barns. Moloney murine leukemia virus-induced tumors: Recombinant proviruses in active chromatin regions. *Nucl. Acids Res.* 10: 577-592, 1982.

Mariman, E.C.M., Ch.A.G. van Eekelen, R.J. Reinders, A.J.M. Barns and W.J. van Venrooij. Adenoviral heterogeneous nuclear RNA is associated with the host nuclear matrix during splicing. *J. Mol. Biol.* 154: 103-119, 1982.

Quint, W., H. van der Putten, F. Janssen and A. Barns. Mobility of endogenous ecotropic murine leukemia viral genomes within mouse chromosomal DNA and integration of a mink cell focus-forming virus-type recombinant provirus in the germ line. *J. Virol.* 41: 901-908, 1982.

Van der Hoorn, F.A., E. Hulsebos, A.J.M. Barns and H.P.J. Bloemers. Molecularly cloned c-mos(rat) is biologically active. *EMBO J.* 1: 1313-1317, 1982.

Barns, A., E. Robanus Maendag, H. van der Putten and W. Quint. The role of the long terminal repeat of retroviruses in integration and expression. In: *Biological consequences of DNA structure and rearrangements*. The Fifth John Innes Symposium. K. F. Chefer, C.A. Cullis, D.A. Hopwood, A.W.B. Johnston and H.W. Woolhouse (eds.). Croom Helm, London, 1983, pp. 93-106.

Quint, W., W. Boelens, P. van Wezenbeek, E. Robanus Meendag and A. Barns. Generation of AKR mink cell focus-forming virus: Nucleotide sequence of the 3' end of a somatically acquired AKR-MCF. *Virology* 136: 425-434, 1984.

Selten, G., H.Th. Cuypers, M. Zijlstra, C. Mellef and A. Barns. Involvement of c-myc in MuLV-induced T cell lymphomas in mice: Frequency and mechanisms of activation. *EMBO J.* 3: 3215-3222, 1984.

Quint, W., W. Boelens, P. van Wezenbeek, Th. Cuypers, E. Robanus Maendag, G. Selten and A. Barns. Generation of AKR mink cell focus-forming viruses: A conserved single-copy xenotropic-like provirus provides recombinant long terminal repeat sequences. *J. Virol.* 50: 432-438, 1984.

Cuypers, H.Th., G. Selten, W. Quint, M. Zijlstra, E. Robanus Meendag, W. Boelens, P. van Wezenbeek, C. Mellef and A. Barns. Murine leukemia virus-induced T-cell lymphogenesis: Integration of proviruses in a distinct chromosome region. *Cell* 37: 141-150, 1984.

Gielkens, A.L.J., J.T. van Oirschot and A.J.M. Barns. Genome differences among field isolates and vaccine strains of pseudorabies virus. *J. Gen. Virol.* 66: 69-82, 1985.

Selten, G., H.Th. Cuypers and A. Barns. Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas. *EMBO J.* 4: 1793-1798, 1985.

Barns, A., A. van der Ouweind, W. Quint, J. van Oirschot and A. Gielkens. Presence of markers for virulence in the unique short region or repeat region or both of pseudorabies hybrid viruses. *J. Virol.* 53: 89-93, 1985.

Barns, A. Onderzoek van lymfoom bij muis toont aan: bepaalde integraties van provirus in DNA van gastheer leiden tot kanker. *Tijdschrift Kenk* Vol.9 nr. 3: 27-28, 1985.

Krimpenfort, P. and A. Berns. Inbrengen van kankergenen in muis leert hoe deze genen werken. Tijdschrift Kanker Vol.9 nr. 4: 27-28, 1985.

Hilkens, J., H.Th. Cuypers, G. Selten, V. Kroezen, J. Hilgers and A. Berns. Genetic mapping of Pim-1 putative oncogene to mouse chromosome 17. Somatic Cell and Molecular Genetics 12: 81-88, 1986.

Cuypers, H.T., G. Selten, A. Berns and A.H.M. Geurts van Kessel. Assignment of the human homologue of Plm-1, a mouse gene implicated in leukemogenesis, to the pter-q12 region of chromosome 6. Hum. Genet. 72: 262-265, 1986.

Pals, S.T., M. Zijlstra, Th. Radaszkiewicz, W. Quint, H.Th. Cuypers, H.J. Schoenmakers, C.J.M. Mellef, A. Berns and E. Gleichmann. Immunological induction of malignant lymphoma: Graft-vs-host reaction-induced B cell lymphomas contain integrations of predominantly ecotropic murine leukemia proviruses. J. Immunol. 138: 331-339, 1986.

Selten, G., H.Th. Cuypers, W. Boelens, E. Robanus-Maandag, J. Verbeek, J. Domen, Ch. van Beveren and A. Berns. The primary structure of the putative oncogene plm-1 shows extensive homology with protein kinases. Cell 46: 603-611, 1986.

Cuypers, H.Th.M., G.C. Selten, M. Zijlstra, R.E. de Goede, C.J. Mellef and A.J. Berns. Tumor progression in murine leukemia virus-induced T-cell lymphomas: Monitoring clonal selections with viral and cellular probes. J. Vir. 60: 230-241, 1986.

Mellef, C.J.M., M. Zijlstra, W.L.E. Vasmel, E. Mathews, R.M. Slater, and A.M. Berns. Mechanisms of lymphoma induction by retroviruses. In: Progress in Immunology VI (Proceedings of the VIth Immunological Congress). Academic Press, Orlando, Florida, USA, 1986: p. 664-674.

Domen, J., M. von Lindern, A. Hermans, M. Breuer, G. Grosveld, A. Berns. Comparison of the human and mouse plm-1 cDNA's: nucleotide sequence and immunological identification of the 'in vitro' synthesized plm-1 protein. Oncogene Research 1: 103-112, 1987.

Krimpenfort, P., and A. Berns. Gene transfer into mammalian embryos. Human Reproduction 2: 333-339, 1987.

Krimpenfort, P., G. Rudenko, F. Hochstenbach, D. Guessow, A. Berns, H. Ploegh. Crosses of two independently derived transgenic mice demonstrate functional complementation of the genes encoding heavy (HLA-B27) and light (B2-microglobulin) chains of HLA class I antigens. EMBO 6: 1673-1676, 1987.

Quint, W., A. Gieikens, J. van Oirschot, A. Berns and H.T. Cuypers. Construction and characterization of deletion mutants of Pseudorabies virus: A new generation of 'live' vaccines. J. Gen. Vir. 68: 523-534, 1987.

Kievits, F., P. Ivanyi, P. Krimpenfort, A. Berns, and H.L. Ploegh. HLA-restricted recognition of viral antigens in HLA transgenic mice. Nature 329: 447-449, 1987.

Berns, A., H.Th. Cuypers, G. Selten and J. Domen. Pim-1 activation in T-cell lymphomas. In: N.O. Kjeldgaard, J. Forchhammer, eds. Viral Carcinogenesis, Alfred Benzon Symposium 24. Munksgaard, Copenhagen: 211-224, 1987.

Berns, A., G. Selten, H.T. Cuypers, J. Domen. The pim-1 oncogene. In: E.P. Reddy, A.M. Skalka, T. Curran, eds. The Oncogene Handbook. Amsterdam, Elsevier, 1988: 121-134.

Berns, A. The generation of transgenic animals and their use in fundamental research. In: A.C. Beynen, H.A. Solleveld, eds. New Developments in Biosciences: Their Implications for Laboratory Animal Science. Proceedings of the Third Symposium of the FELASA. Dordrecht, M.Nijhoff, 1988: 175-183.

Berns, A. Proivirus tagging as an instrument to identify oncogenes and to establish synergism between oncogenes. Review in: *Archives of Virology* 102: 1-18, 1988.

Berns, A. De muis als proefmodel voor oncogenen. In: *De smalle grens tussen gezond en kwaadaardig: over nieuwe ontwikkelingen in het kankeronderzoek*. Borst P, ed. Rapport No A88/4 Gezondheidsraad, 1988; 17-23.

Blöthmann, H., P. Kisielow, Y. Uematsu, M. Melissen, P. Krimpenfort, A. Berns, H. von Boehmer, M. Steinmetz. T-cell-specific deletion of T-cell receptor transgenes allows functional rearrangements of endogenous α - and β -genes. *Nature* 334: 156-159, 1988.

Krimpenfort, P., R. de Jong, Y. Uematsu, Z. Dembic, S. Ryser, H. von Boehmer, M. Steinmetz, A. Berns. Transcription of T cell receptor β -chain genes is controlled by a downstream regulatory element. *EMBO* 7: 745-750, 1988.

Krimpenfort, P.J., G. Schaart, F.R. Pieper, F.C. Reemakers, H.T. Cuypers, R.M. van den Heuvel, W.T. Vree Egberts, G.J. van Eys, A. Berns, H. Bloemendaal. Tissue-specific expression of a vimentin-desmin hybrid gene in transgenic mice. *EMBO* 7: 941-947, 1988.

Nusse, R., A. Berns. Cellular oncogene activation by insertion of retroviral DNA: Genes identified by provirus tagging. In: G. Klein, ed. *Cellular Oncogene Activation*. New York, Marcel Dekker, 1988: 95-119.

Steinmetz, M., Z. Dembic, S. Ryser, P. Krimpenfort, A. Berns, Y. Uematsu, H. von Boehmer. Transfer of T-cell receptor genes into cloned T-cells and fertilized mouse eggs. In: M.M. Devis, J. Keppler, eds. *The T-cell receptor*. New York: Alan R. Liss Inc. UCLA 73: 199-207, 1988.

Uematsu, Y., S. Ryser, Z. Dembic, P. Borgulya, P. Krimpenfort, A. Berns, H. von Boehmer, M. Steinmetz. In transgenic mice the introduced functional T cell receptor β gene prevents expression of endogenous β genes. *Cell* 52: 831-841, 1988.

Van Zijl, M., W. Quint, J. Braire, T. de Rover, A. Gielkens, A. Berns. Regeneration of herpesviruses from molecularly cloned subgenomic fragments. *JVIR* 62: 2191-2195, 1988.

Berns, A., P. Krimpenfort. Transgenic mice as an instrument to study genetic defects. In: Gorrod/Albano/Papa, eds. *Molecular Aspects of Human Disease*. Chichester, England: Ellis Horwood Limited. Vol.1, 1989: 129-133.

Berns, A., M. Breuer, S. Verbeek, M. van Lohuizen. Synergism between oncogenes in T-cell lymphomagenesis. In: H. Lother, R. Dernick, W. Osterteg (eds.), *NATO Advanced Study Institute Series, subserie Cell Biology*, Vol. 34, pp. 343-353. Springer Verlag, Berlin, 1989.

Berns, A., M. Breuer, S. Verbeek, M. van Lohuizen. Transgenic mice as a means to study synergism between oncogenes. *Int. J. Cancer*, Suppl. 4: 22-25, 1989.

van Lohuizen, M., M. Breuer, A. Berns. N-myc is frequently activated by proviral insertion in MuLV-induced T cell lymphomas. *EMBO J.* 8: 133-136, 1989.

van Lohuizen, M., S. Verbeek, P. Krimpenfort, J. Domen, C. Seris, T. Redaszkiewicz, A. Berns. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. *Cell* 56: 673-682, 1989.

Breuer, M.L., H.T. Cuypers, A. Berns. Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. *EMBO J.* 8: 743-747, 1989.

Breuer, M., R. Siebos, S. Verbeek, M. van Lohuizen, E. Wientjens, A. Berns. Very high frequency of lymphoma induction by a chemical carcinogen in gim-1 transgenic mice. *Nature* 340: 61-63, 1989.

Pieper, F.R., G. Schaart, P.J. Krimpenfort, J.B. Hendrik, H.J. Moshage, A. van de Kemp, F.C. Reemakers, A. Berns, H. Bloemendaal. Transgenic expression of the muscle-specific intermediate filament protein desmin in nonmuscle cells. *J. Cell. Biol.* 108: 1009-1024, 1989.

Krimpenfort, P., Y. Uematsu, Z. Dembic, M. Steinmetz, A. Berns. The transcription of the T cell receptor B-chain gene is controlled by a downstream regulatory element. In: A.L. Beaudet, R. Mulligan, I.M. Verma (eds.) *Gene Transfer and Gene Therapy. UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 87*, pp.117-127 (Alan R. Liss, Inc. New York, 1989).

Krimpenfort, P., F. Ossendorp, J. Borst, C. Mellef, A. Berns. T-cell depletion in transgenic mice carrying a mutant for TCR β . *Nature* 341: 742-746, 1989.

Bonneville, M., I. Ishida, P. Mombaerts, M. Katsuki, S. Verbeek, A. Berns, S. Tonegawa. Blockage of $\alpha\beta$ T-cell development by TCR gd transgenes. *Nature* 342: 931-934, 1989.

Tonegawa, S., A. Berns, M. Bonneville, A. Farr, I. Ishida, K. Ito, S. Itohara, C.A. Janeway, Jr., O. Kanagawa, M. Katsuki, R. Kubo, J. Lafaille, P. Mombaerts, D. Murphy, N. Nakanishi, Y. Takagaki, L. Van Kaer, S. Verbeek. Diversity, development, ligands, and probable functions of gd T cells. In: *Cold Spring Harbor Symposia on Quantitative Biology, Volume LIV*, pp. 31-44 (Cold Spring Harbor Laboratory Press, 1989).

Berns, A. Identification of synergizing oncogenes in T- and B-cell lymphomagenesis. In: *Mechanisms of B cell neoplasia 1989* (Roche, Basel, Switzerland): 243-250, 1989.

Bonneville, M., I. Ishida, S. Itohara, S. Verbeek, A. Berns, O. Kanagawa, W. Haas, S. Tonegawa. Self-tolerance to transgenic gd T cells by intrathymic inactivation. *Nature* 344: 163-165, 1990.

Bonneville, M., S. Itohara, E.G. Krecko, P. Mombaerts, I. Ishida, M. Katsuki, A. Berns, A.G. Farr, C.A. Janeway, Jr., Tonegawa, S. Transgenic mice demonstrate that epithelial homing of gd T cells is determined by cell lineages independent of T cell receptor specificity. *J. Exp. Med.* 171: 1015-1026, 1990.

Ishida, I., S. Verbeek, M. Bonneville, S. Itohara, A. Berns, S. Tonegawa. T-cell receptor gd and gd transgenic mice suggest a role of a g gene silencer in the generation of $\alpha\beta$ T cells. *PNAS* 87: 3067-3071, 1990.

Wu, H., J.F. Bateman, A. Schnieke, A. Sharpe, D. Barker, T. Mascara, D. Eyre, R. Bruns, P. Krimpenfort, A. Berns, R. Jaenisch. Human-mouse interspecies collagen I heterotrimer is functional during embryonic development of Mov13 mutant mouse embryos. *Mol. Cell. Biol.* 10: 1452-1460, 1990.

van Zijl, M., H. van der Gijden, N. de Wind, A. Gielkens, A. Berns. Identification of two of two genes in the unique short region of pseudorabies virus; comparison with herpes simplex virus and varicella-zoster virus. *J. Gen. Virol.* 71: 1747-1755, 1990.

de Wind, N., A. Zijderveld, K. Glazenburg, A. Gielkens, A. Berns. Linker insertion mutagenesis of herpesviruses: Inactivation of single genes within the Us region of pseudorabies virus. *J. Virol.* 64: 4691-4696, 1990.

Klein, J.C., M.J. Bleeker, J.T. Lutgerink, W.J. van Dijk, H.F. Brugghe, H. van den Elst, G.A. van der Marel, J.H. van Boom, J.G. Westra, A.J.M. Berns, E. Kriek. Use of shuttle vectors to study the molecular processing of defined carcinogen-induced DNA damage: mutagenicity of single O⁴-ethylthymine adducts in HeLa cells. *Nuc. Acids Res.* 18: 4131-4137, 1990.

te Riele, H., E. Robanus Maandag, A. Clarke, M. Hooper, A. Berns. Consecutive inactivation of both alleles of the *pim-1* proto-oncogene by homologous recombination in embryonic stem cells. *Nature* 348: 649-651, 1990.

Jacobs, H., H. Von Boehmer, C.J.M. Mellef, A. Berns. Mutations in the major histocompatibility complex class I antigen-presenting groove affect both negative and positive selection of T cells. *Eur. J. Immunol.* 20: 2333-2337, 1990.

van Lohulzen, M., A. Berns. Tumorigenesis by slow-transforming retroviruses - an update. *BBA Reviews in Cancer* 1032: 213-235, 1990.

Verbeek, S., M. van Lohulzen, M. van der Valk, J. Domen, G. Kraai, A. Berns. Mice bearing the $\text{E}\mu$ -*myc* and $\text{E}\mu$ -*pim-1* transgenes develop pre-B-cell leukemia prenatally. *Mol. Cell. Biol.* 11: 1176-1179, 1991.

Breuer, M., E. Wientjens, S. Verbeek, R. Siebos, A. Berns. Carcinogen-induced lymphomagenesis in *pim-1* transgenic mice: dose dependence and involvement of *myc* and *ras*. *Cancer Res.* 51: 958-963, 1991.

Saris, C.J.M., J. Domen, A. Berns. The *pim-1* oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. *EMBO J.* 10: 655-664, 1991.

Berns, A. Separating the wheat from the chaff. *Current Biology* 1: 28-29, 1991.

van Lohulzen, M., S. Verbeek, B. Scheijen, E. Wientjens, H. van der Gulden, A. Berns. Identification of cooperating oncogenes in $\text{E}\mu$ -*myc* transgenic mice by provirus tagging. *Cell* 65: 737-752, 1991.

Berns, A., M. van Lohulzen, S. Verbeek, J. Domen, C. Saris. Transgenic mice as a model system to study synergism between oncogenes. In: *CSH "Origins of Human Cancer, a Comprehensive Review*. Eds. J. Brugge, T. Curran, E. Harlow, F. McCormick, pp. 791-801, 1991.

van der Lugt, N., E. Robanus Maandag, H. te Riele, P.W. Laird, A. Berns. *pgk-hprt* as a selectable marker for targeting of genes in mouse embryonic stem cells: disruption of the T-cell receptor δ -chain-encoding gene. *Gene* 105: 263-267, 1991.

van Zijl, M., G. Wensvoort, E. de Kluyver, M. Hulst, H. van der Gulden, A. Gieikens, A. Berns, R. Moormann. Live attenuated Pseudorabies virus expressing envelope glycoprotein E1 of hog cholera virus protects swine against both Pseudorabies and hog cholera. *J. Virol.* 65: 2761-2765, 1991.

Möröy, T., S. Verbeek, A. Ma, P. Achacoso, A. Berns, F. Alt. $\text{E}\mu$ N- and $\text{E}\mu$ L-*myc* cooperate with $\text{E}\mu$ -*pim-1* to generate lymphoid tumors at high frequency in double transgenic mice. *Oncogene* 6: 1941-1948, 1991.

Berns, A. Tumorigenesis in transgenic mice: Identification and characterization of synergizing oncogenes. *J. Cell. Biochem.* 47: 130-135, 1991.

Laird, P.W., A. Zijderveld, K. Linders, M. Rudnicki, R. Jaenisch, A. Berns. Simplified mammalian DNA isolation procedure. *Nucl. Acids Res.* 19: 4294, 1991.

Van Lohulzen, M., M. Frasch, E. Wientjens, A. Berns. Sequence similarity between the mammalian *bmi-1* proto-oncogene and the *Drosophila* regulatory genes *Psc* and *Su(z)2*. *Nature* 353: 353-355, 1991.

Berns, A. The search for complementing oncogenes. In: *Hereditary Tumors*. Eds. M.L. Brandi and R. White. Serono Symposia Publications from Raven Press. Vol. 83 pp. 101-107, 1991.

Kimman, T.G., N. de Wind, N. Oei-Lie, J.M.A. Poi, A.J.M. **Berns**, A.L.J. Gieikens. Contribution of single genes within the unique short region of Aujeszky's disease virus (swine herpesvirus type 1) to virulence, pathogenesis and immunogenicity. *J. Gen. Virol.* 73: 243-251, 1992.

Klein, J.C., M.J. Bleeker, C.P. Saris, H. Roelen, H. Brugghe, H. van der Elst, G. van der Marel, J. van Boom, J. Westra, E. Kriek, and A. **Berns** (1992). Repair and replication of plasmids with site-specific 8-oxodG and 8-AAFdG residues in normal and repair-deficient human cells. *Nucl. Acids Res.* 20: 4437-4443.

te Riele, H., E. Robanus Maandag, A. **Berns**. Highly efficient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs. *Proc. Natl. Acad. Sci. USA* 89: 5128-5132, 1992.

Ossendorp, F., H. Jacobs, G. van der Horst, E. de Vries, A. **Berns**, J. Borst. T cell receptor- $\alpha\beta$ lacking the β -chain V domain can be expressed at the cell surface but prohibits T cell maturation. *J. Immunol.* 148: 3714-3722, 1992.

Clarke, A., Robanus Maandag, E., van Roon, M., van der Lugt, N., van der Valk, M., Hooper, M., **Berns**, A., and te Riele, H. (1992). requirement for a functional Rb-1 gene in murine development. *Nature* 359, 328-330.

de Wind, N., J. Domen, A. **Berns** (1992). Herpesviruses encode an unusual protein-serine/threonine kinase which is nonessential for growth in cultured cells. *J. Virol.* 66: 5200-5209

Acton, D., J. Domen, H. Jacobs, M. Vlaar, S. Korsmeyer, A. **Berns**. Collaboration of pim-1 and bcl-2 in lymphomagenesis (1992) *Current Topics in Microbiology and Immunology*: 182, 293-298.

de Wind, N., Wagenaar, F., Poi, J., Kimman,T., and **Berns**, A. (1992). The Pseudorabies virus homolog of the Herpes Simplex Virus UL21 gene product is a capsid protein which is involved in capsid maturation. *J. Virol.* 66:7096-7103.

Kimman, T., J. Poi., N. De Wind, N. Oei-Lie, A. **Berns**, and A. Gieikens (1992). Role of different genes in the virulence and pathogenesis of Aujeszky's disease virus. *Vet. Microbiol.* 33: 45-52.

de Wind, N., **Berns**, A., Gieikens, A., and Kimman, T. (1993) Ribonucleotide reductase-deficient mutants of pseudorabies virus are avirulent for pigs and induce partial protective immunity. *J. gen Virol.* 74: 351-359.

Domen, J., van der Lugt, N., Laird, P., Saris, C., Clarke, A., Hooper, M., and **Berns**, A. (1993) Impaired IL-3 response in pim-1 deficient bone marrow derived mast cells. *BLOOD*, 82, 1445-1452

Domen, J., N. van der Lugt, A. Clarke, M. Hooper and A. **Berns**. Level of Pim-1 protein affects the size and proliferative capacity of B cell progenitor compartment (1993) *J. Exp. Med.* 178, 1665-1673.

Domen, J., van der Lugt, N.M.T., Laird, P.W., Saris, C.J.M. and Berns, A. 1993. Analysis of Pim-1 function in mutant mice. *Leukemia* 7, S108-S112.

Laird, P., van der Lugt, N., Clarke, A., Domen, J., Linderts, K., McWhir, J., **Berns**, A., Hooper, M. A. (1993) Phenotype of pim-1 deficient mice. *Nucl. acids Res.* 21, 4750-4755.

Alkema, M., J. Wiegant, A. Raap, A. **Berns** and M. van Lohuizen. Characterization and chromosomal localization of the human proto-oncogene BMI-1 (1993). *Hum. Mol. Gen.* 2, 1597-1603.

Smit, J., Schinkel, A., Oude Elferink, R., A. groen, E. Wagenaar, L. van Deemter, C. Mol., R. Ottenhoff, N. van der Lugt., M. van Roon., M. van der Valk., G. Offerhaus, A. **Berns**, and P. Borst (1993).

Disruption of the murine mdr2 glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. *Cell*, 75, 451-462.

Berns, A. 1994. Is p53 the only real tumor suppressor gene? *Curr. Biol.* 4:137-139

Renauld, J.-C., N. van der Lught, A. Vink, M. van Roon., C. Godfrain., G. Warnier., H. Metz., A. Feller., A. **Berns**, and J. Van Snick, 1994. Thymic lymphomas in interleukin 9 transgenic mice. *Oncogene* 9:1327-1332

N. van der Lught, J. Domen, K. Linders, M. van Roon, E. Robanus Maandag, H. te Riele, M. van der Valk, J. Deschamps, M. Sofroniew, M. van Lohuizen, and A. **Berns** (1994). Posterior transformation, neurological abnormalities and severe hematopoietic defects in Icsc with a targeted deletion of the bmi-1 proto-oncogene. *Genes & Development*, 8:757-769.

H. Jacobs, D. Vandepitte, L. Tolkamp, E. de Vries, J. Borst, and A. **Berns**. 1994. CD3 components at the surface of pro-T cells can mediate pre-T cell development *in vivo*. *Eur. J. Immunol.* 24: 934-939.

De Wind, N., Peeters, B.H., Zijderveld, A., Gielkens, A.L.J., **Berns**, A.J.M., Kimman, T.G., 1994. Mutagenesis and Characterization of 41 kilobase-pair region of the pseudorabies virus genome: Transcription map, search for virulence genes, and comparison with homologs of herpes simplex virus type 1. *Virology*, 200:784-790.

Schinke, A.H., Smit, J.M., van Tellingen, O., Beijnen, J.H., Wagenaar, E.W., van Deemter, L., Mol, C.A.A.M., van der Valk, M., Robanus Maandag, E.C., te Riele, H.P.J., **Berns**, A.J.M., and Borst, P. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to deficiency in the blood-brain barrier and to increased sensitivity to drugs. *Cell* 77:491-502.

Habets, G.G.M., Scholte, E.H.M., Zuydgeest, D., van der Kammen, R.A., Stam, J.C., **Berns**, A., and Collard, J.G. 1994. Identification of an invasion-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins. *Cell* 77: 537-549.

Robanus Maandag, E., M. van der Valk, M. Vlaar, C. Feitkamp, J. O'Brien, M. van Roon, N. van der Lught, A. **Berns** and H. te Riele. 1994. Developmental rescue of an embryonic-lethal mutation in the retinoblastoma gene in chimeric mice. *EMBO J.* 13, 4260-4268.

Klein, J.C., Bleeker, M.J., Roelen, H.C.P.F., Rafferty, J.A., Margison, G.P., Brugge, H.F., van der Elst, H., van der Marel, G.A., van Boom, J.H., Kriek, E., and **Berns**, A. 1994. Role of nucleotide excision repair in processing of O-4 alkylthymines in human cells. *J. Biol. Chem.* 269:5521-25528.

Bain, G., Robanus Maandag, E., Izon, D.J., Amsen, D., Kruisbeek, A.M., Weintraub, B., Krop, I., Schissel, S., Feeney, A.J., van Roon, M., van der Valk, M., te Riele, H.P.J., **Berns**, A., and Murre, C. 1994. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. *Cell* 79: 865-892.

Berns, A., van der Lught, N., Alkema, M., van Lohuizen, M., Domen, J., Acton, D., Allen, J., Laird, P.W., and Jonkers, J. 1995. Mouse models to study multistep tumorigenesis. *CSH Quant. Biol.* Symp. in press.

LUND'S UNIVERSITET
Institutionen för Medicinska
och Fysiologiska Kemi



UNIVERSITY OF LUND
Department of Medical and
Physiological Chemistry

Dr. Anton Berns
Head Section Molecular Genetics
The Netherlands Cancer Institute
Plesmanlaan 121
1066 CX Amsterdam
The Netherlands

Lund, October 21, 1991

Dear Dr. Berns,

I do recall that we met last October in Freiburg in Rolf Kemler's laboratory. I was there as a participant in an EMBO course of embryonic stem technology that was headed by Rolf Kemler. I also remember that you gave a very interesting lecture about PIM-1 oncogene during lymphomatosis and in normal development. I tried to contact you over the phone last Friday but you were not there so talked to one of your collaborators whose name I did not write down. Therefore I hereby ask you if it is possible for me to get some of your very good genomic library made from 129 mouse in addition to an ES cell line called E14 which primarily comes from Hooper. A friend of mine, Dr. Björn Vennström at Karolinska Institutet, Stockholm, told me that he very kindly got those items from your laboratory. I am going to do homologous recombination with a gene coding a 62 kDa liver protein which we suspect probably affects the skeletal development during the embryogenesis in mouse. Since most of the ES cells available are cloned from 129 mice I would like to isolate the gene from an isogenic genomic library to be able to increase the events of homologous recombination.

Sincerely yours

Anders Frenzen
Anders Frenzen
Ass. professor

Department of Physiological Chemistry
P.O. Box 94
S-221 00 LUND
SWEDEN

Tel.no: 46 46 108578
Fax.no: 46 46 113417

Postal address
P.O. Box 94
S-221 00 LUND
SWEDEN

Telephone
Tel. 046-10 70 00 (+1)
Int. +46 46 10 70 00

Telex: Chemsemin, SWEDEN
Tel.no: 33552 LUNIVER 8
Telex: +46 46 11 16 17

MAX-PLANCK-INSTITUT FÜR PSYCHIATRIE

DEUTSCHE FORSCHUNGSANSTALT FÜR PSYCHIATRIE

AM KLOPPERSPITZ 18A
8033 PLANEGG-MARTINSRIED

Max-Planck-Institut für Psychiatrie
Am Klopperspitze 18a 8033 Planegg-Martinsried

TELEFON 089 85781
DURCHWAHL 8578 / 3648
TELEX 621740 mpmde

23.09.91

Dear Dr. Rieke,

We are writing to you concerning the interesting results you presented at a meeting in Heidelberg recently, namely, that in gene targeting experiments, targeting constructs made from syngenic DNA are more effective than those made from isogenic DNA. We have started to use gene targeting methodology as a tool in our studies of the nervous system and in order to optimise the system we would extremely eager to use constructs made from isogenic genomic clones.

Therefore, we would be very grateful if you could send us an aliquot of the genomic bank from the mouse strain 129. The library would not be distributed outside of this Dept. without your permission and we would be happy to share our results with you.

Looking forward to hearing from you soon,

Yours sincerely,

Prof. Hans Thoenen.

Hans Thoenen
Dr. Yasuo Masu.
Yasuo Masu
Dr. Patrick Carroll.
Patrick Carroll

FAX NO. 149-89-8578-2749

ZÜRICH UNIVERSITY MEDICAL SCHOOL
Institute of Physiology

Facsimile Transmission of ...1... page(s) incl. this page

Date: 29.12.92
To: Dr. A. Berns
Dr. H. te Riele
Div. of Molecular Genetics
Fax: 0031 20 512 1998
Bsn

From
Dr. Max Gassmann, DVM
Institute of Physiology
University of Zürich-Irchel
Winterthurerstr. 190
CH-8057 Zürich
SWITZERLAND

Tel. + 41 1 257 5051
Fax + 41 1 364 0564

Dear Dr. Berns
Dear Dr. te Riele

I am writing to request the 129-derived genomic DNA library used for your Rb gene targeting experiments published in PNAS (June 92).

I am presently working at the University of Zürich after leaving Paul Berg's lab at Stanford 3 months ago. My goal is to continue my postdoctoral work on the characterization of a polyoma-based vector which replicates autonomously in ES cells (a poster was presented this summer at the CSH mouse meeting). Since such a vector might increase the frequency of homologous recombination I would like to do some targeting experiments using isogenic DNA. My lab is mainly interested in the regulation of the erythropoietin gene expression.

Since I will also join the meeting "Progress in Cancer Research" to be held at Lausanne (Switzerland) next month, I would be delighted if you could bring the library with you. Please be assured that we will mention you in any publication concerning this work. I am looking forward to see you soon. Thank you very much for your time and consideration. I wish you a happy New Year.

Sincerely,

Max Gassmann
cc. Hg 30/12 17/1/93

M A X - P L A N C K - G E S E L L S C H A F T Z U R
FÖRDERUNG DER WISSENSCHAFTEN E.V.

Arbeitsgruppe "Zellteilungsregulation & Gensubstitution"

H u m b o l d t U n i v e r s i t ä t

Postanschrift:

Dr. Anton Berns
Division of Molec. Genetics
Netherlands Cancer Institute
and Dept. Biochem. University
Pleamaalaan 121
1066 CX Amsterdam
Nederlanden

Max-Delbrück-Haus
R-Röntgen-Str. 10
D-1115 Berlin-Duch
Tel.: +49 30/9463307
FAX: +49 30/9463306

Berlin, d. 27.7.92

Hein Quenzer

Dear Dr. Berns,

I like to congratulate you and your coworkers to the outstanding results you have recently published in P.N.A.S. I think this is a great breakthrough in homologous recombination.

I would be very interested to use your approach to inactivate the Rb gene in differentiated cell types like epithelial cells. We have recently published a paper in Oncogene describing the inactivation of pRb synthesis by antisense oligonucleotides which led to stimulation of cell division. In the mean time we can do this even better with antisense constructions and ribozymes. With your efficiencies of homol. recombination it is obviously possibly to achieve the knockout of both alleles successfully or even at the same time.

We are particularly interested in the knockout of the Rb gene in hepatocytes for several reasons. I would like to ask you if you are willing to collaborate on this matter. I can think of two alternatives. One would be to send one of my coworkers to your lab who is experienced in all essential techniques. The other alternative would be if you provide us with your targeting vectors and we try it on our own. In case of success, the results could be published together. I would be very pleased if you would be interested to collaborate on this matter.

Looking forward to your answer.
Yours sincerely,

Michael Strauss
Michael Strauss, Ph.D.

Reantwortet am 8/07/92

MAX - DELBRÜCK - LABORATORIUM IN DER MAX-PLANCK-GESELLSCHAFT

Carl-von-Linnae-Weg 10, D - 5000 Köln 30, Tel: 0221-5062 620 FAX: 0221-5062 613

Dr. Carmen Birchmeier

Dr. Anton Berns
The Netherlands Cancer Institute
Division of Molecular Genetics
Meemanaan 121
1066 CX Amsterdam
The Netherlands

5.11.1991

Dear Dr. Berns,

For our further knock-out experiments, we want to use genomic clones from an 129 Sv library and I would therefore appreciate, if you could send us an aliquot from your 129 Sv library. The institute my group and I are working at, the Max-Delbrück-Laboratory in the Max-Planck-Society, is a noncommercial research facility funded by the german government. It is understood that we will not distribute this library further without your consent.

Yours sincerely



Dr. Carmen Birchmeier

Dr. Richard P. Harvey
The Walter and Eliza Hall Institute of Medical Research
Post Office, Royal Melbourne Hospital
Victoria 3050
AUSTRALIA
phone 61-3-3452485 facsimile 61-3-3470852

17.9.91

Dr. Anton Berns
Division of Molecular Genetics of the Netherlands Cancer Institute
Plesmanlaan 121
1066CX Amsterdam
Netherlands

Dear Anton,

It was good to bump into you again at the Wellcome gene targeting course in London. I have tried to get onto Stratagene about a 129 genomic library but that seems premature. I thought I would get in before the hoards and ask whether you could send me some of your library for our immediate needs. Of course, I understand if your stocks have been stretched by similar requests.

Yours sincerely and best wishes,



Richard Harvey

kosten berekenen

Kernforschungszentrum Karlsruhe

Kernforschungszentrum Karlsruhe GmbH, Postfach 1640, D-7500 Karlsruhe 1

Dr. Anton Berns
Department of Virology
Anton van Leeuwenhoekhuis
The Netherlands Cancer Institute
Plesmanlaan 121
NL-1066 CX Amsterdam
The Netherlands

Institut für Genetik und für Toxikologie von Spaltstoffen

Leiter: Prof. Dr. P. Herrlich
Prof. Dr. D. M. Taylor

Datum: October 8, 1991/lk
Beantworten:
Telefon: 07247/823292
Ihre Meldung:
FAX: 49 7247 82 3336

Dear Toni.

It was a pleasure to meet you and be influenced by your stimulating science orientation. As you had suggested we should first pull our gene out of the homologous ES cell library. Can we please use yours? We will meanwhile discuss the possibilities of knock-out constructs. I will then come back and ask for your advice if I may.

Thanks in advance.

regards.

yours



Peter Herrlich
Professor of Genetics
University of Karlsruhe
and
Director, Institute of Genetics and Toxicology
Kernforschungszentrum Karlsruhe

Kernforschungszentrum Karlsruhe GmbH mit beschränkter Haftung, Abteilung für Biotechnologie, Einrichtungen und Verwaltung:
W-7514 Eggenstein-Leopoldshafen, Tel. 07247/823292, Telefax 724718 - KFZ-Nummer: W-1500 Karlsruhe, Wappenstraße 8
Vorstand: Dr. Alexander Kühn, Vizevorstand: Prof. Dr. Hermann Wagner, Stellv. Vizevorstand: Prof. Dr. Hans-Joachim Hohenstein, Prof. Dr. Werner Kühn
Handelsregister: Amtsgericht Karlsruhe, HRB 202, Siedlungsmittelbergschule Seite A4, Karlsruhe, Amts-Nr. 002471300 (BLZ 680 000 20), Correspondenz-Nr. 14, Karlsruhe
Kfz-Nr. 2211320 (BLZ 680 000 10), Gewerbeamt Amts-Nr. 022451 (BLZ 680 700 00); Umlaufmerk-Nr. A4, Karlsruhe, Amts-Nr. 022432000 (BLZ 680 001 01)

Dr. Anton Berns
Netherlands Cancer Institute
Plesmanlaan 121
1066 CX Amsterdam

Klaus Küstner
Institute for Cell and
Tumor Biology
IKFZ
Im Neuenheimer Feld
6900 Heidelberg

Heidelberg, 8-15-1991

Dear Dr. Berns,

During the recent "Wellcome Summer School on Gene Targeting and Homologous Recombination" in London you stressed the importance of the use of isogenic DNA for targeting experiments. I would greatly appreciate if you could supply us with an aliquot of an amplified genomic 129 or E14 library for our targeting experiments. Thank you in advance.

Sincerely

Klaus Küstner

Genentech, Inc.

460 Point San Bruno Boulevard
South San Francisco, CA 94080
(415) 266 1000
TWX: 910371760

Dr. Anton Berns
The Netherlands Cancer Institute
Division of Molecular Genetics
Plesmanlaan 121
1066 CX Amsterdam
The Netherlands


Dear Dr. Berns:

I recently attended the Mouse Molecular Genetics Meeting in Heidelberg and noted with interest your results with Isogenic DNA. I would be very interested in obtaining this 129 library from you.

I have recently begun working at Genentech where I would use this library. Please let me know what agreements or conditions would be needed.

If possible, please contact me by FAX (415-266 2739), or telephone collect (415-266 1984) with your response. I look forward to hearing from you.

Sincerely,


Mark W. Moore, Ph.D.

\$50 = Kosten berekening

Dear Dr. Berns,

I would like to request the use of your 129 genomic library. I am a Senior member of the Department of Molecular Genetics at Hoffmann La-Roche and my lab is one floor above Andy McMahon's who has obtained your library. With your permission, I can get the library from him. Our aim is to create knockouts in the mouse V-cam and F1 AM-1 genes. We are currently characterizing the mouse cDNAs for these genes and now need to pull out genomic. Actually we have ELAM genomics already from a BalbC library but would like to compare targeting frequencies with constructs from your 129 library.

I would greatly appreciate your help. We will not give out the library to anyone without your permission. If we can use your library please fax us a letter.

Sincerely,

Mark

Dr. Mark Labow
Department of Molecular Genetics
Hoffmann La-Roche Inc.
340 Kingsland St
Nutley, NJ 07110-1199

phone: 201-235-7073
Fax: 201-235-7617



Howard Hughes Medical Institute
Research Laboratories / Seattle

University of Washington School of Medicine
Med Stop SL-15
Seattle, Washington 98195

Richard D. Palmiter, Ph.D.
Investigator
Telephone (206) 543-6090

3 September 1991

Dr. Anton Berns
Netherlands Cancer Institute
Amsterdam

Dear Anton,

It was good to see you again. I want to thank you for being chairperson once again. It was a very good session and the last talk was especially good! I was also glad to hear that you will become a co-organizer in future years. I feel assured that the meeting is in good hands. It is really not very much work, but after four years I think it is good to get some fresh input.

I wanted to follow up on the observations that Heintz and Rieke discussed regarding the importance of using strain 129 DNA for homologous recombination in ES cells. We have been trying to target the dopamine beta-hydroxylase gene with great difficulty (about 1/800 neor^R cells are targeted) and would like to isolate the gene from your 129 lambda library, if necessary. We would certainly use it for all new gene isolations as well since it cannot hurt. Thus, if you would be willing to send an aliquot of your 129 lambda library I would be most grateful.

If you use Federal Express you can bill it to me by using the following numbers:


Under payment: check the box, "bill third party" and enter 1253-3198-0

Under billing reference: enter 027-756

The Federal express address is: Howard Hughes Mod Inst, Univ of WA Health Sci
Bldg 1 605, Seattle WA 98195
Phone (206) 543-6064

Thank you very much.

Sincerely,


Richard Palmiter

UNIVERSITE
LIBRE DE
BRUXELLES

FACULTE DE MEDECINE
INSTITUT DE HISTOLOGIE
INTERDISCIPLINAIRE
BIOLOGIE HUMAINE
ET NUCLÉAIRE
CP 462

CAMPUS HOPITAL ERASME
ROUTE DE L'YNA 402
1070 BRUXELLES
BELGIQUE
TEL : 323 41.3741.39
FAX : 323 41.374

Dr Hein Te Riele
Division of Molecular Genetics
The Netherlands Cancer Institute
Plesmanlaan 121
1066 CX Amsterdam
The Netherlands

ULB

October 1, 1991.

Dear Dr Te Riele,

As a follow up of our phone conversation, I would be interested in obtaining your genomic library derived from mouse strain 129. We are primarily interested in the development of homologous recombination in ES cells using genes of the G protein coupled family of receptors. We are ready to pay all charges related to the shipment of this material and will not distribute the library without your prior consent. In case you send the package via Federal Express, you can charge our account number 1360-1622-9.

I thank you for your kind consideration, and I remain,

Sincerely yours,

Parmentier
M. Parmentier

I.R.I.B.H.N.
ULB Campus Erasme
Building C 5th floor, room 135
808 route de Lennik
B-1070 Brussels Belgium
Phone 32-2-555 41 72
Fax 32-2-555 46 55





Jeffrey D. Saffer

The Jackson Laboratory

Bar Harbor, Maine 04609

(207) 288-3371

BERNS et al.
Serial No.: 08/216,121
EXHIBIT N



Research Scientist

Dr. Anton Berns
Department of Molecular Genetics
The Netherlands Cancer Institute
Plesmanlaan 121
1066 CX Amsterdam
The Netherlands

December 13, 1991


Dear Dr. Berns:

I am writing for two reasons. The first is to thank you and Dr. te Riele for sending the retinoblastoma targeting vectors and probes. As Ken Paige probably described, we are setting up a gene targeting lab. We had tried some preliminary experiments with a targeting vector for the uncoupling protein gene without success. We appreciate your sharing your clones with us so that we could demonstrate that we could carry out homologous recombination with good vectors. In accordance with your results, we have been successful getting fairly efficient homologous recombination with your clone. This exercise has been most useful for us in working out the methods.

Second, given the potential benefits of using 129-derived clones in the targeting vectors, I would like to get your 129 lambda genomic library. We would appreciate this greatly.

Thanks again for your help.

Sincerely,



Jeffrey D. Saffer

P.S. Ken says "Hi and thanks".

cc. Hein

MAX-DELBRÜCK-LABORATORIUM

In der Max-Planck-Gesellschaft

Carl-von-Ossietzky-Weg 10, D-5000 Köln 30, Germany, Tel: 49-221-5062 615, Fax: 49 221 5062 613
Dr. Silvia Stabel

Dr. Anton Berns
Division of Molecular Genetics
Netherlands Cancer Institute
Plesmanlaan 121
NL - 1066 CX Amsterdam

21st September 1992

Dear Dr. Berns,
with interest I read your paper which appeared in June this year in PNAS
(to Riele et al.).

Together with Achim Gossler here in the Institute we have been trying to
target the protein kinase C- γ gene in the D-3 cell line with non-isogenic
DNA and have not been successful so far.

Apart from other factors which might affect the targeting frequency and
which we also try to change we would also like to use isogenic DNA for our
next attempt. Therefore I would like to ask you, if you would make
available your 129 genomic DNA library for our targeting project.
I thank you very much in advance if you can help us in this matter.

With best regards

Silvia Stabel

Dr. Silvia Stabel

cc. Henry 24/9

verschwend 30/07/92

Baris

INSTITUT FÜR GENETIK
der Universität zu KÖLN


Weyertal 18a
D-5000 Köln 41
Tel.: (+49 221) 470-5457
Telex: 8888881 unik
Telefax: (+49 221) 470-5188

20 July 1992

Dear Dr. te Riele,

I am a post-doctoral fellow working in Klaus Rajewsky's laboratory at the Institute for Genetics in Cologne and am writing to ask if it would be possible to obtain the 129-derived genomic library which you have used successfully? Thank-you very much in advance.

Sincerely,



Raul M. Torres Ph.D.

Institute for Genetics
University of Cologne
121 Weyertal
D-5000 Cologne 51
Germany

phone: (49 221) 470 34 16
fax: (49 221) 470 5185

CC: → Dennis
23/7/92